The United States Food and Drug Administration (FDA) has approved two new biosimilar medicines based on golimumab, creating a major milestone for patients living with chronic autoimmune diseases. Accord BioPharma announced that the FDA approved Immgolis and Immgolis Intri as biosimilars to Simponi and Simponi Aria. These approvals introduce the first FDA-approved golimumab biosimilars in the U.S. healthcare market.
The decision is expected to improve treatment access for adults with moderately to severely active rheumatoid arthritis and ulcerative colitis. Many patients who rely on biologic therapies face significant financial challenges because these medicines can be expensive. The launch of biosimilar options often helps increase competition and lower treatment costs over time.
Immgolis and Immgolis Intri also received interchangeable designation from the FDA for approved indications, an important regulatory distinction that may simplify substitution at the pharmacy level in certain states.
This development highlights the growing role of biosimilars in modern healthcare and signals continued expansion in the autoimmune disease treatment market.
Immgolis, known scientifically as golimumab-sldi, is a biosimilar to Simponi. It is administered as a subcutaneous injection and has been approved for adults with moderately to severely active rheumatoid arthritis in combination with methotrexate, as well as adults with moderately to severely active ulcerative colitis.
Immgolis Intri, also known as golimumab-sldi for intravenous use, is a biosimilar to Simponi Aria. It is approved for adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.
Both medicines belong to a class of drugs known as tumor necrosis factor blockers, commonly referred to as TNF blockers. These therapies work by targeting inflammation in the body, which plays a key role in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis.
Golimumab therapies have been used for years in the treatment of autoimmune conditions. However, until now, patients in the United States did not have access to a biosimilar version of these medications.
The FDA approval of Immgolis and Immgolis Intri is significant for several reasons.
First, the approval introduces the first golimumab biosimilars in the United States. Biosimilars are highly similar to existing biologic drugs and are designed to provide comparable safety, effectiveness, and quality.
Second, these approvals may improve affordability and access for patients who need long-term biologic treatment. Autoimmune diseases often require ongoing therapy, and treatment costs can place a heavy burden on patients and healthcare systems.
Third, the interchangeable designation could help streamline access. An interchangeable biosimilar can be substituted for the reference biologic product in certain situations, depending on state laws and pharmacy regulations.
Industry experts continue to view biosimilars as a major opportunity to reduce healthcare spending while maintaining high treatment standards.
Rheumatoid arthritis is a chronic autoimmune disease that causes the immune system to mistakenly attack healthy joints. Over time, this can lead to pain, stiffness, swelling, and permanent joint damage.
The disease can also affect other organs and tissues throughout the body. Many patients experience fatigue, reduced mobility, and difficulty completing daily activities.
Biologic therapies such as golimumab are often prescribed when traditional treatments fail to adequately control symptoms. TNF blockers help reduce inflammation and may slow disease progression.
Because rheumatoid arthritis typically requires lifelong management, patients often need consistent access to effective medications. The availability of biosimilars may help reduce treatment barriers and expand access to advanced therapies.
Ulcerative colitis is another chronic inflammatory condition approved for treatment with Immgolis. The disease affects the lining of the large intestine and rectum, causing inflammation and ulcers.
Common symptoms include abdominal pain, diarrhea, rectal bleeding, weight loss, and fatigue. Severe cases can significantly reduce quality of life and may require hospitalization or surgery.
TNF blockers are commonly used when conventional therapies fail to control moderate to severe disease activity. By reducing inflammation, these medicines can help patients achieve remission and manage symptoms more effectively.
The introduction of a biosimilar option may provide new opportunities for patients seeking affordable long-term treatment.
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, continues to expand its biosimilar portfolio.
The company stated that it plans to commercialize Immgolis and Immgolis Intri in the United States during the fourth quarter of 2026. According to company leadership, the goal is to improve patient access to affordable biologic therapies.
Accord BioPharma already markets several biosimilar and specialty products across oncology, immunology, and central nervous system treatment categories. The organization has publicly announced plans to bring 20 biosimilars to the U.S. market by 2030.
This strategy reflects a larger industry trend as pharmaceutical companies invest heavily in biosimilar development to address rising healthcare costs.
Bio-Thera Solutions developed Immgolis and Immgolis Intri and will continue managing manufacturing and product supply.
The company, headquartered in Guangzhou, China, focuses on innovative biologic therapies and biosimilars for cancer, autoimmune diseases, cardiovascular disorders, and other serious medical conditions.
International collaboration between developers and commercialization partners has become increasingly common in the biosimilar industry. These partnerships often combine manufacturing expertise with regional market access and regulatory capabilities.
Although biosimilars are designed to match the reference product closely, they still carry important risks and safety warnings.
Immgolis and Immgolis Intri include boxed warnings related to serious infections and malignancies.
According to prescribing information, patients receiving golimumab products may face increased risks of severe infections, including tuberculosis, bacterial infections, invasive fungal infections, and opportunistic infections. Some infections have led to hospitalization or death.
Healthcare providers are advised to test patients for latent tuberculosis before beginning treatment and monitor them during therapy.
The medicines are also associated with potential malignancy risks, including lymphoma and other cancers reported in children and adolescents treated with TNF blockers.
Additional warnings include:
Patients should discuss all risks and treatment options with a qualified healthcare provider before starting therapy.
For Immgolis, the most commonly reported side effects in adults include:
For Immgolis Intri, commonly reported side effects include:
Patients should promptly report any unusual symptoms or signs of infection to their healthcare provider.
Biosimilars continue to play a growing role in the global pharmaceutical market.
Unlike traditional generic drugs, biosimilars are complex biologic medicines developed to closely match an existing biologic product. Because biologics are produced from living cells, biosimilar development requires extensive analytical testing and clinical evaluation.
Regulatory agencies such as the FDA require biosimilars to demonstrate no clinically meaningful differences in safety, purity, and potency compared with the original product.
As patents expire on major biologic medicines, more biosimilar products are expected to enter the market. Industry analysts believe this trend could generate billions of dollars in healthcare savings over the coming years.
Patients, insurers, healthcare systems, and providers are increasingly embracing biosimilars as confidence in these therapies grows.
One notable aspect of the FDA approval is the interchangeable designation granted to Immgolis and Immgolis Intri for approved indications.
An interchangeable biosimilar meets additional FDA standards beyond biosimilarity alone. The designation means the product is expected to produce the same clinical result as the reference product in any given patient.
For medications administered more than once, manufacturers must also demonstrate that switching between the biosimilar and the original biologic does not increase safety risks or reduce effectiveness.
Interchangeability can simplify pharmacy substitution practices, although laws vary by state.
This designation may help accelerate biosimilar adoption and improve patient access to lower-cost biologic treatment options.
The launch of the first golimumab biosimilars could intensify competition within the autoimmune treatment market.
Biologic therapies generate billions of dollars annually, making biosimilars an attractive area for pharmaceutical companies. Increased competition may encourage price reductions, broader insurance coverage, and expanded patient access.
Healthcare experts often emphasize that lower-cost biosimilars can help reduce financial pressure on healthcare systems while maintaining treatment quality.
At the same time, physicians and patients may require education regarding biosimilar safety, effectiveness, and interchangeability.
The long-term success of Immgolis and Immgolis Intri will likely depend on pricing strategies, payer support, physician confidence, and patient adoption.
Accord BioPharma stated that Immgolis and Immgolis Intri are expected to become commercially available in the United States during the fourth quarter of 2026.
The company plans to distribute the medicines exclusively in the U.S. market.
As additional biosimilars enter the market, healthcare providers and patients may gain access to a wider range of treatment choices for autoimmune diseases.
The FDA approval of Immgolis and Immgolis Intri represents a major milestone in the biosimilar market and autoimmune disease treatment landscape.
For the first time, patients in the United States will have access to biosimilar versions of golimumab therapies used to treat rheumatoid arthritis and ulcerative colitis.
The approval may improve affordability, expand treatment access, and strengthen competition within the biologics market. At the same time, patients and healthcare providers should remain aware of the important safety considerations associated with TNF blockers.
As biosimilar adoption continues to rise, these therapies are expected to become an increasingly important part of modern healthcare.
Immgolis is a biosimilar version of Simponi, containing golimumab-sldi. It is approved for adults with moderately to severely active rheumatoid arthritis and ulcerative colitis.
Immgolis Intri is a biosimilar version of Simponi Aria for intravenous use in adults with moderately to severely active rheumatoid arthritis.
An interchangeable biosimilar meets additional FDA standards that allow pharmacy substitution under certain state regulations.
The FDA requires biosimilars to demonstrate comparable safety and effectiveness to the original biologic medicine.
Accord BioPharma expects both products to launch in the United States during the fourth quarter of 2026.
This article is intended for informational and educational purposes only and should not be considered medical advice, diagnosis, or treatment guidance. Always consult a licensed healthcare professional before starting, stopping, or changing any medication or treatment plan. The information in this article may not include all possible side effects, warnings, or drug interactions associated with Immgolis or Immgolis Intri.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.